Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Farne, Hugo A ^a   Cates, Christopher J ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; OLODATEROL; SALMETEROL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL FUMARATE; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL; SALMETEROL XINAFOATE; SCOPOLAMINE DERIVATIVE;

ALL CAUSE MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; META ANALYSIS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; ETHANOLAMINES; FORMOTEROL FUMARATE; HUMANS; INDANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALMETEROL XINAFOATE; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE;

EID: 84979862597     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008989.pub3     Document Type: Review

References (173)

1. Aaron SD, Vandemheen K, Ferguson D, FitzGerald M, Maltais F, Boureau J, et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal 2004;11(8):581-5.
2. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine 2007;146(8):545-55.
3. Kaplan A. Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal 2007;16(4):258-60.
4. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63(11):962-7.
5. Roisman G. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique 2007;63(6):390-1.
6. Buhl R, Abrahams R, Bjermer L, Derom E, Flezar M, Hebert J, et al. Pooled safety analysis of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1-year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts).
7. Buhl R, Derom E, Ferguson G, Pizzichini E, Reid J, Watz H, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes versus mono-components in COPD in two 1-year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188-9.
8. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). European Respiratory Journal 2015;45(4):969-79. [PUBMED: 25573406]
9. Chia M, Reid J, Buhl R, Abrahams R, Bjermer L, Derom E, et al. Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77.
10. Chia M, Reid J, Buhl R, Derom E, Ferguson G, Maltais F, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77.
11. NCT01431274. Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431274 (accessed 15 April 2015). [NCT01431274]
12. Buhl R, Abrahams R, Bjermer L, Derom E, Flezar M, Hebert J, et al. Pooled safety analysis of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in patients with chronic obstructive pulmonary disease: two 1-year studies. Chest. American College of Chest Physicians, 2014; Vol. 146 (4 meeting abstracts).
13. Buhl R, Derom E, Ferguson G, Pizzichini E, Reid J, Watz H, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes versus mono-components in COPD in two 1-year studies. Thorax. BMJ Publishing Group, 2014; Vol. 69:A188-9.
14. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). European Respiratory Journal 2015;45(4):969-79. [PUBMED: 25573406]
15. Chia M, Reid J, Buhl R, Abrahams R, Bjermer L, Derom E, et al. Safety of once-daily tiotropium and olodaterol fixed-dose combination via the Respimat in chronic obstructive pulmonary disease in two 1-year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77.
16. Chia M, Reid J, Buhl R, Derom E, Ferguson G, Maltais F, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies. Respirology. Blackwell Publishing, 2015; Vol. 20:77.
17. NCT01431287. Tiotropium + olodaterol fixed dose combination (FDC) versus tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01431287 (accessed 15 April 2015). [NCT01431287]
18. Hoshino M. Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD. Respirology 2014;44(Suppl 58):4668.
19. Hoshino M, Ohtawa J. Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology 2014;19:403-10.
20. A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341]
21. Balkissoon R. Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012;9(4):439-41.
22. Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67(9):781-8. [PUBMED: 22544891]
23. Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Combining once-daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13-18, Denver, Colorado. 2011:183.
24. NCT00846586. Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00846586 (accessed 15 April 2015). [NCT00846586]
25. A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3901 (accessed 6 August 2015). [CQAB149B2341]
26. Balkissoon R. Journal club. COPD: Journal of Chronic Obstructive Pulmonary Disease 2012, 2012;9(4):439-41.
27. Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67(9):781-8. [PUBMED: 22544891]
28. Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S. Combining once-daily bronchodilators In COPD: indacaterol plus tiotropium versus tiotropium alone. Proceedings of the American Thoracic Society 2011 International Conference, 2011 May 13-18, Denver, Colorado. 2011:183.
29. NCT00877383. Efficacy and safety of indacaterol plus tiotropium versus tiotropium alone in patients with chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT00877383 (accessed 15 April 2015). [NCT00877383]
30. NCT00139932. Tiotropium bromide alone vs tiotropium bromide and formoterol fumarate in subjects with COPD (Study P04272). ClinicalTrials.gov/show/NCT00139932 (accessed 15 April 2015). [NCT00139932]
31. Tashkin D, Varghese S. Formoterol treatment plus tiotropium results in greater improvements in lung function compared with tiotropium administered alone in patients with COPD [Abstract]. Journal of Allergy and Clinical Immunology 2007;119(1 Suppl):S4 [13].
32. Tashkin D, Varghese S. The therapeutic effect of treatment with formoterol plus tiotropium was greater than the effect of treatment with tiotropium alone in COPD: findings from a 12-week, multicenter, double-blind, placebo-controlled, trial. Chest 2007;132(4):529a.
33. Tashkin DP. Formoterol and tiotropium reduces rescue medication use more than tiotropium alone in patients with moderate COPD: findings from a 12 week randomized placebo controlled trial [Abstract]. American Thoracic Society International Conference; 2008 May 16-21; Toronto 2008:A647[#F5].
34. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 2009;6(1):17-25.
35. Tashkin DP, Pearle JL, Varghese S. Improvement of lung function with coadministered formoterol and tiotropium, regardless of smoking status in patients with chronic obstructive pulmonary disease [Abstract]. Chest 2008;134(4):103002s.
36. Arievich H, Potena A, Fonay K, Vogelmeier CF, Overend T, Smith J, et al. Formoterol given either alone or together with tiotropium reduces the rate of exacerbations in stable COPD patients [Abstract]. European Respiratory Journal 2006;28(Suppl 50):440s [P2514].
37. NCT00134979. Formoterol Certihaler, tiotropium HandiHaler and tiotropium HandiHaler in combination with formoterol Certihaler in patients with stable chronic obstructive pulmonary disease co-administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT00134979 (accessed 15 April 2015). [NCT00134979]
38. Novartis. A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10μg b.i.d., tiotropium HandiHaler 18μg o.d. and tiotropium HandiHaler 18μg o.d. in combination with formoterol Certihaler 10μg b.i.d. in patients with stable chronic obstructive pulmonary disease. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=1591 (accessed 6 August 2015). [CFOR258F2402]
39. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respiratory Medicine 2008;102(11):1511-20.
40. Vogelmeier CF, Harari SA, Fonay K, Beier J, Overend T, Till D, et al. Formoterol and tiotropium both improve lung function in stable COPD patients with some additional benefit when given together [Abstract]. European Respiratory Journal 2006;28(Suppl 50):429s [P2506].
41. Abrahams R, Allen L, Hernandez G, Ting N, ZuWallack R. Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12-week studies. Chest. 2014; Vol. 146 (4 meeting abstracts):47A. [DOI: 10.1378/chest.1994418]
42. NCT01694771. Co-administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01694771 (accessed 15 April 2015). [NCT01694771]
43. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double-blind studies. Chest 2014;146 (4 meeting abstracts):70A.
44. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. International Journal of Chronic Obstructive Pulmonary Disease 2014;9:1133-44.
45. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double-blind studies. International Journal of Chronic Obstructive Pulmonary Disease 2014;146 (4 meeting abstracts):46A.
46. Abrahams R, Allen L, Hernandez G, Ting N, Wallack RZ. Safety of the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate 12-week studies. Chest. 2014 (4 meeting abstracts):47A.
47. NCT01696058. Co-administration of olodaterol Respimat® and tiotropium HandiHaler®. clinicaltrials.gov/show/NCT01696058 (accessed 15 April 2015). [NCT01696058]
48. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Combined use of olodaterol Respimat and tiotropium HandiHaler shows additional lung function improvement in COPD compared with tiotropium: results from two randomized, double-blind studies. Chest 2014;146 (4 meeting abstracts):70A.
49. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies. International Journal of Chronic Obstructive Pulmonary Disease 2014;9:1133-44.
50. ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Health status of patients with COPD receiving the combination of olodaterol Respimat and tiotropium HandiHaler compared with tiotropium: results from two replicate, randomized, double-blind studies. International Journal of Chronic Obstructive Pulmonary Disease 2014;146 (4 meeting abstracts):46A.
51. Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Pivovarova A, Schmidt O, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD. European Respiratory Journal 2012;40(Suppl 56):P2882.
52. Banerji D, Fedele M, Chen H. Once-daily dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Chest 2014;145 (meeting abstracts):3.
53. Barnes N, Bateman E, Gallagher N, Green Y, Horton R, Henley M, et al. QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study [Abstract]. Thorax 2012;67(Suppl 2):A147-8.
54. Bateman ED, Hodder R, Miravitlles M, Lee A, Towse L, Serby C. A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life. European Respiratory Journal 2001;18(Suppl 33):26s.
55. Bateman E, Hashimoto S, Gallagher N, Green Y, Horton R, Henley M, et al. Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study [Abstract]. Thorax 2012;67(Suppl 2):A148-9.
56. Bateman E, Ferguson GT, Barnes N, Gallagher N, Green Y, Horton R, et al. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. European Respiratory Journal 2012;40(Suppl 56):2810.
57. Bateman ED, Welte T, Hashimoto S, Gallagher N, Green Y, Horton R, et al. Dual bronchodilation with once-daily QVA149 provides superior bronchodilation compared to its mono-components and tiotropium in all subgroups of patients with COPD: the SHINE study. American Journal of Respiratory and Critical Care Medicine 2013;187:A4263.
58. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. European Respiratory Journal 2013;42(6):1484-94.
59. Beeh KM, Korn S, Beier J, Jadayel D, Henley M, Tylek J, et al. QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study [Abstract]. Thorax 2012;67 (Suppl 2):A147 [P191].
60. Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respiratory Medicine 2014;108(4):584-92.
61. Beier J, van Noord J, Deans A, Brooks J, Maden C, Baggen S, et al. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2012;7:153-64.
62. Brusasco V, Menjoge SS, Kesten S. Flow and volume responders following treatment with tiotropium and salmeterol in patients with COPD [Abstract]. Proceedings of the American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. 2003:B024 Poster 420.
63. Canto ND, Ribeiro JP, Neder JA, Chiappa GR. Addition of tiotropium to formoterol improves inspiratory muscle strength after exercise in COPD. Respiratory Medicine 2012;106(10):1404-12.
64. Chapman KR, Bateman ED, Gallagher N, Hu H, Kim HJ, Banerji D. Once-daily QVA149 improves lung function, dyspnea and health status regardless of disease severity and prior medications: the SHINE study [Abstract]. Respirology 2013;18(Suppl 4):31 [OS100].
65. Chapman KR, Bateman ED, Gallagher N, Hu H, Banerji D. P234 QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study. Thorax 2013;68(Suppl 3):A182-3.
66. Chapman K, Bateman E, Gallagher N, Hu H, Banerji D. Once-daily QVA149 improves lung function, dyspnea, and health status independent of disease severity and prior medications: the SHINE study. Chest 2014;145.
67. D'Urzo A, Mahler DA, Decramer M, Worth H, White T, Alagappan VKT, et al. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. Thorax 2013;68:P236. [DOI: 10.1136/thoraxjnl-2013-204457.388]
68. D'Urzo A, Mahler D, Worth H, White T, Alagappan V, Chen H, et al. Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: the BLAZE study. Chest 2014;145 (3 meeting abstract).
69. D'Urzo A, Mahler D, Worth H, White T, Alagappan V, Chen H, et al. Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: the BLAZE study. Chest 2014;145 (3 meeting abstracts).
70. Decramer M, Wedzicha JA, Sandstrom T, Niewoehner D, Fowler Taylor A, D'Andrea P, et al. Safety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine 2013;187 (meeting abstracts):A1479.
71. Derom E, Westerman J, Gronke L, Hamilton A, Li C, Beeh KM. The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease. Thorax 2014;69:A190-1.
72. Di Marco F, Carlucci P, Cazzola M, Verga M, Mondoni M, Pistone A, et al. A single dose of formoterol (FOR) and tiotropium (TIO) reduce hyperinflation in COPD patients [Abstract]. European Respiratory Journal 2003;22(Suppl 45):P1844.
73. Ficker J, Wedizicha J, Taylor AF, D'Andrea P, Arrasate C, Chen H. QVA149 improves lung function and reduces exacerbations compared with tiotropium in patients with severe-to-very severe COPD: the SPARK study. Chest 2014;145 (3 meeting abstracts). [NCT01120691]
74. Frith P, Thompson P, Wark P, Lindstrom S, Bateman E. Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [Abstract]. Respirology 2013;18(Suppl 2):20 [O041].
75. Fujimoto K, Komatsu Y, Kanda S, Itou M, Yoshikawa S, Yasuo M, et al. Comparison of clinical efficacy of tiotropium and salmeterol for pulmonary function, air-trapping, exercise capacity, and HRQO in COPD [Abstract]. Respirology 2007;12(Suppl 4):A164.
76. Fujimoto K, Yamazaki H, Ura M, Kitaguchi Y. Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD [Abstract]. European Respiratory Journal 2014;44(Suppl 58):P897.
77. Fujimoto K, Yamazaki H, Ura M. Efficacy of mono-therapy with tiotropium or indacaterol or the. Respirology (Carlton, Vic.) 2014;19(Suppl 3):101.
78. Gross NJ, Paulson D, Kennedy D, Korducki L, Kesten S. A comparison of maintenance tiotropium and salmeterol on arterial blood gas tensions in patients with COPD [Abstract]. Respiratory Care 2003;48(11):1081.
79. Horhota ST, van Noord JA, Verkleij CB, Bour LJ, Sharma A, Trunk M, et al. In vitro, pharmacokinetic, pharmacodynamic, and safety comparisons of single and combined administration of tiotropium and salmeterol in COPD patients using different dry powder inhalers. AAPS Journal 2015;17(4):871-80.
80. Imran M, Chhabra SK, Kotwani A. Combinations of long acting beta2 agonists to. Archives of Pharmacy Practice 2015;6(2):19-23.
81. Jayaram L, Wong C, McAuley S, Rea H, Zeng I, O'Dochartaigh C. Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6-minute walk test. Journal of Chronic Obstructive Pulmonary Disease 2013;10(4):466-72.
82. Jones CDS. The combined effect of tiotropium and formoterol on the functional status of patients with moderate-to-severe COPD [Dissertation]. CINAHL Accession Number: 2011033276//UMI Order AAI3408930 2010:144 p. [978-112-405-5602602]
83. Mahler DA, Decramer M, D'Urzo AD, Worth H, White T, Alagappan V, et al. Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. American Journal of Respiratory and Critical Care Medicine 2013;187:A6070.
84. Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VKT, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. European Respiratory Journal 2014;43(6):1599-609.
85. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg. Respiratory Medicine 2014;108(12):1752-60.
86. Meyer T, Brand P, Reitmeir P, Scheuch G. Effect of formoterol, salbutamol and tiotropium bromide on the efficacy of lung clearance in patients with COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2008 May 16-21; Toronto. 2008:A646[#F1].
87. Mezzi K, Fedele MChen H, Banerji D. LABA/LAMA dual bronchodilation as a paradigm shift in COPD therapy: overview of the QVA149 ignite program. Chest 2014;145.
88. Mezzi K, Wedzicha JA, Decramer M, Fowler Taylor A, Fogel R, Chen H, et al. QVA149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract]. Proceedings of the 7th International Primary Care Respiratory Group (IPCRG) World Conference Athens. 2014.
89. NCT00394485. Tiotropium + procaterol vs tiotropium + placebo in COPD patients. clinicaltrials.gov/show/NCT00394485 (accessed 15 April 2015). [NCT00394485]
90. NCT00424528. Efficacy safety study of arformoterol/tiotropium combination versus either therapy alone in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT00424528 (accessed 15 April 2015). [NCT00424528]
91. NCT00668772. Tiotropium/salmeterol inhalation powder in COPD. clinicaltrials.gov/show/NCT00668772 (accessed 15 April 2015). [NCT00668772]
92. NCT00673478. Tiotropium and salmeterol PK study in COPD patients. clinicaltrials.gov/show/NCT00673478 (accessed 15 April 2015). [NCT00673478]
93. NCT00680056. Add-on effects of tiotropium over formoterol in exercise tolerance on chronic obstructive pulmonary disease patients. clinicaltrials.gov/show/NCT00680056 (accessed 15 April 2015). [NCT00680056]
94. NCT00696020. Combination of orally inhaled BI1744CL/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT00696020 (accessed 15 April 2015). [NCT00696020]
95. NCT01040403. Determining optimal free dose combination of tiotropium bromide and BI 1744 CL in chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01040403 (accessed 15 April 2015). [NCT01040403]
96. NCT01285492. A 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of QVA149 (110 mcg indacaterol / 50 mcg glycopyrrolate o.d.) using tiotropium (18 mcg o.d.) as an active control in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT01285492 (accessed 15 April 2015).
97. NCT01559116. Characterization of 24-hour lung function profiles of inhaled tiotropium + olodaterol fixed dose combination in patients suffering from chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT01559116 (accessed 15 April 2015). [NCT01559116]
98. NCT02238119. Efficacy and safety of free combination of tiotropium + formoterol compared to formoterol and tiotropium in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT02238119 (accessed 15 April 2015). [NCT02238119]
99. NCT02242240. Lung function changes following the addition of formoterol to tiotropium in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT02242240 (accessed 15 April 2015). [NCT02242240]
100. NCT02242253. Free combinations of tiotropium inhalation powder capsule + salmeterol metered dose inhaler, tiotropium inhalation powder capsule and salmeterol metered dose inhaler in patients with chronic obstructive pulmonary disease (COPD). clinicaltrials.gov/show/NCT02242253 (accessed 15 April 2015). [NCT02242253]
101. New J, Hanania N, Matovinovic E, Tashkin D. Adding nebulized formoterol to tiotropium treatment provides added benefits in pulmonary function, dyspnea and rescue medication use: a pooled analysis [Abstract]. Proceedings of the American Thoracic Society International Conference; 2009 May 15-20; San Diego. 2009:A4541 [Poster #J51].
102. Nicolini A. Short term effects of tiotropium on COPD patients treated with long acting bronchodilators. Tanaffos 2012;11(1):26-31.
103. Orevillo C, Gotfried M, Denenberg M, Fernandez C, Darken P, St Rose E, et al. Combination glycopyrronium and formoterol fumarate inhalation aerosol (PT003) at a dose of 14.4/9.6 g provides superior improvement in inspiratory capacity compared to tiotropium dry powder inhaler (DPI) in subjects with moderate to severe COPD (Abstract). American Journal of Respiratory and Critical Care Medicine 2014;189:A3759.
104. Reisner C, Fernandez C, Orevillo C, St. Rose E, Kollar C. Pearl therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva(R) HandiHaler(R) and placebo in patients with COPD. Proceedings of the American Thoracic Society 2012 International Conference, 2012 May 18-23; San Francisco, California. 2012:A2926.
105. Reisner C, Rennard SI, Fogarty C, Fischer T, St Rose E, Fernandez C, et al. Pearl Therapeutics' combination LAMA/LABA MDI (GFF-MDI, PT003) provides a significant benefit on home peak expiratory flow rate (PEFR) and reduces the need for rescue albuterol use compared io its components administered alone, Spiriva(R) Handihaler(R), and Foradil(R) Aerolizer(R) in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [Abstract]. American Journal of Respiratory and Critical Care Medicine 2012;185:A2259.
106. Reisner C, Gotfried M, Denenberg MB, Fernandez C, St Rose E, Fortner P, et al. Low doses of Pearl Therapeutics' LAMA/LABA combination MDI (GFF MDI, PT003) provide superior bronchodilation compared to components and to open-label Spiriva HandiHaler in a randomized, double-blind, placebo-controlled phase IIb study in patients with COPD. American Journal of Respiratory and Critical Care Medicine 2013;187 (meeting abstracts):A2434.
107. Salvi S, Brashier B, Gothi D, Karkhanis V, Madas S, Gogtay J, et al. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD. Pulmonary Pharmacology and Therapeutics 2014;27(1):90-5.
108. Setoguchi Y. The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status [Abstract]. European Respiratory Journal 2014;44(Suppl 58):P896.
109. Tashkin DP, Hanania NA, McGinty J, Denis-Mize K, Chaudry I. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Advances in Therapy 2009;26(11):1024-34.
110. ten Hacken NH, van der Haart H, Grevink R, Thompson S, Roemer W, Postma DS. Bronchodilation improves endurance but not muscular efficiency in COPD [Abstract]. Proceedings of the American Thoracic Society International Conference; 2007 May 18-23; San Francisco 2007:Poster #M72.
111. Van Noord J, Aumann J, Janssens E, Mueller A, Cornelissen P. Relation between the acute response to salbutamol and long term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T=F) in COPD patients [abstract]. European Respiratory Journal 2003;22(Suppl 45):153.
112. van Noord JA, Qumann J, Janssens E, Mueller A, Cornelissen PJ. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract]. Proceedings of the American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003:B024 Poster 421.
113. van Noord JA, Smeets JJ, Otte A, Bindels H, Mueller A, Cornellissen PJG. The effect of tiotropium, salmeterol and it's combination on dynamic hyperinflation in COPD [Abstract]. Proceedings of the American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego, California. 2005:[B93] [Poster: 310].
114. Wark P, Chapman K, Bateman E, Olsson P, Chen H, Banerji D, et al. Effect of QVA149 on lung function in the subgroup of patients. Respirology (Carlton, Vic.) 2015;20:81.
115. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respiratory Medicine 2013;1(3):199-209.
116. Wedzicha JA, Decramer M, Ficker J, Niewoehner DE, Sandstrom T, Fowler Taylor A. Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. American Journal of Respiratory and Critical Care Medicine 2013;187 (meeting abstracts):A2429.
117. Wedzicha JA, Decramer M, Ficker JH, Sandstrom T, Taylor AF, D'Andrea P, et al. Qva149 provides greater improvement in patient reported symptom scores compared to glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK study [Abstract]. American Journal of Respiratory and Critical Care Medicine 2014;189:A3761.
118. Wedzicha J, Ficker J, Niewohner D, Sandstrom T, Fowler Taylor A, Banerji D. Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: the SPARK study. Chest 2014;145(3):406A.
119. Wedzicha J, Ficker J, Fowler Taylor A, D'Andrea P, Arrasate C, Chen H, et al. Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: the SPARK study. Chest 2014;145(3):427A.
120. Wedzicha JA, D'Urzo A, Mezzi K, Chen H, Banerji D, Fogel R. QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: the SPARK study [Abstract]. European Respiratory Journal 2014;44(Suppl 58):1893.
121. Evdokimov V, Evdokimova A, Tebloev K, Zolotova O. Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease. European Journal of Heart Failure Abstracts Supplement 2014;16(Suppl 2):251.
122. Evdokimov V, Evdokimova A, Tebloev K, Kovalenko E, Kozhina N, Zolotova O. Efficacy and safety of different types of bronchodilator therapy in patients with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease. European Heart Journal 2014;35:385-6.
123. Evdokimov V, Evdokimova A, Sheyanov M, Kozhina N. Clinical efficacy and safety of formoterol and tiotropium administration in patient with chronic heart failure due to coronary artery disease combined with chronic obstructive pulmonary disease. European Journal of Heart Failure 2015;17(Suppl 1):68.
124. Maltais F, Galdiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Thorax. BMJ Publishing Group, 2014; Vol. 69:A186-7.
125. Maltais F, Iturri JBG, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. European Respiratory Journal. European Respiratory Society, 2014; Vol. 44.
126. NCT01525615. A study to determine the effect of tiotropium + olodaterol fixed dose combination on exercise endurance time during constant work load cycle test in COPD. clinicaltrials.gov/show/NCT01525615 (accessed 15 April 2015). [NCT01525615]
127. NCT01536262. Japan long-term safety for tiotropium plus olodaterol. clinicaltrials.gov/show/NCT01536262 (accessed 15 April 2015). [NCT01536262]
128. NCT01964352. Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 1). clinicaltrials.gov/show/NCT01964352 (accessed 15 April 2015). [NCT01964352]
129. NCT02006732. Tiotropium + olodaterol fixed dose combination (FDC) in chronic obstructive pulmonary disease (OTEMTO 2). clinicaltrials.gov/show/NCT02006732 (accessed 15 April 2015). [NCT02006732]
130. NCT02296138. Comparing the efficacy of tiotropium + olodaterol (5/5 g) fixed dose combination (FDC) over tiotropium 5g in reducing moderate to severe exacerbations in patients with severe to very severe chronic obstructive pulmonary disease. clinicaltrials.gov/show/NCT02296138 (accessed 15 April 2015). [NCT02296138]
131. Sadigov A, Akhundov S, Bagirov R. Analysis of chronic obstructive pulmonary disease exacerbations with the triple therapy compared with dual and single bronchodilator therapy: which treatment is better for patients with severe disease?. Chest 2014;145(3):425A.
132. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MMK, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD001104.pub2]
133. Barr RG, Bourbeau J, Camargo Carlos A. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2]
134. Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. Advances in Therapy 2009;26(7):691-9. [0741-238X: (Print)]
135. Beier J, Beeh KM. Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:237-43. [1178-2005: (Electronic)]
136. Berger WE, Nadel JA. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease. Respiratory Medicine 2008;102(2):173-88. [0954-6111: (Print)]
137. Burke JP, Eastment JG, Bowman RV, Fong KM, Yang IA. Glycopyrronium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010798]
138. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007;356(8):775-89.
139. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. Journal of Pharmacology and Experimental Therapeutics 2011;337(3):600-9. [PUBMED: 21357659]
140. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics 2010;23(4):257-67.
141. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; Vol. 137, issue 1:20-30. [1931-3543: (Electronic)]
142. Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.CD009552.pub2]
143. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2;: CD009157]
144. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD updated 2015. www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf (accessed 9 July 2015).
145. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org.
146. Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medicine Journal 2010;40(5):364-71.
147. Johnson M. The beta-adrenoceptor. American Journal of Respiratory and Critical Care Medicine 1998;158(5 Pt 3):S146-53.
148. Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD009039.pub2]
149. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2]
150. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3]
151. Kesten S, Plautz M, Piquette CA, Habib MP, Niewoehner DE. Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal 2007;30(5):898-906.
152. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database of Systematic Reviews 2014, issue 3. [DOI: 10.1002/14651858.CD010844.pub2]
153. Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. International Journal of Chronic Obstructive Pulmonary Disease 2014;9:697-714. [PUBMED: 25045258]
154. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD003793.pub3]
155. Moen MD. Indacaterol: in chronic obstructive pulmonary disease. Drugs 2010;70(17):2269-80. [0012-6667: (Print)]
156. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008;63(11):962-7.
157. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD010509.pub2]
158. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance. www.nice.org.uk/guidance/cg101/resources/cg101-chronic-obstructive-pulmonary-disease-update-costing-report2 (accessed 9 July 2015).
159. Proskocil BJ, Fryer AD. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proceedings of the American Thoracic Society 2005;2(4):305-10.
160. The Nordic Cochrane Centre; The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre; The Cochrane Collaboration, 2012.
161. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD. Chest 2008;133(5):1079-87.
162. Jones P. St George's Respiratory Questionnaire for COPD patients (SGRQ-C). www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ-C%20uk%20orig%202005.pdf (accessed 9 July 2015).
163. Singh S. Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD. Evidence Based Medicine 2009;14(2):42-3.
164. Tanaka Y, Horinouchi T, Koike K. New insights into beta-adrenoceptors in smooth muscle: distribution of receptor subtypes and molecular mechanisms triggering muscle relaxation. Clinical and Experimental Pharmacology and Physiology 2005;32(7):503-14.
165. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal Medicine 2008;359(15):1543-54.
166. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respiratory Medicine 2008;102(4):479-87.
167. van der Meer RM, Wagena E, Ostelo RWJG, Jacobs AJE, van Schayck O. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD002999]
168. Wallukat G. The beta-adrenergic receptors. Herz 2002;27(7):683-90.
169. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, issue 5. [DOI: 10.1002/14651858.CD007891.pub3;: CD007891]
170. World Health Organization. Chronic respiratory diseases: chronic obstructive pulmonary disease (COPD). www.who.int/respiratory/copd/en/ (accessed 10 March 2015).
171. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat inhaler and the risk of death in COPD. New England Journal of Medicine 2013;369(16):1491-501.
172. Zwerink M, Brusse-Keizer M, van der Valk PD, Zielhuis GA, Monninkhof EM, van der Palen J, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD002990.pub3;: CD002990]
173. 2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD008989.pub2]